Understanding how eIF6 affects protein production in cells
Mechanism and Regulation of eIF6 in Translation
['FUNDING_R01'] · SAINT LOUIS UNIVERSITY · NIH-11071998
This study is looking at a protein called eIF6 that helps make the building blocks for proteins in our cells, and it aims to find out how this protein works and how it might be used to develop new treatments for certain cancers and genetic disorders, potentially helping patients by slowing down cancer growth without harming healthy cells.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SAINT LOUIS UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11071998 on ClinicalTrials.gov |
What this research studies
This research investigates the role of eIF6, a crucial factor in the assembly of ribosomes, which are essential for protein synthesis in cells. It aims to understand how eIF6 is regulated and its impact on the maturation of ribosomal subunits, particularly in the context of certain cancers and genetic disorders. By studying the mechanisms that control eIF6 release, the research seeks to identify potential therapeutic strategies that could inhibit cancer growth while sparing normal cells. Patients may benefit from insights gained into how targeting eIF6 could lead to new cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with specific cancers associated with eIF6 deregulation, such as certain types of leukemia and breast cancer.
Not a fit: Patients with cancers or conditions unrelated to eIF6 or ribosomal dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically target cancer cells while minimizing effects on healthy cells.
How similar studies have performed: Previous research has shown promising results in targeting similar mechanisms in cancer treatment, indicating potential for success in this approach.
Where this research is happening
SAINT LOUIS, UNITED STATES
- SAINT LOUIS UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ORIGANTI, SOFIA — SAINT LOUIS UNIVERSITY
- Study coordinator: ORIGANTI, SOFIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.